Loading stock…

Genmab A/S (GMAB) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

GMABGenmab A/S

Revenue FY25$3.0B

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+21%9

Revenue, next 1Y+17%8

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+749%10

EPS growth, FY27E+26%8

EPS growth, FY28E+70%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 21%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 70%/yr vs revenue 18%/yr), so margins should widen.

WATCH

Revenue grew 21%/yr over the last 3 years; forecasts see it cooling to 18%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

GMABGenmab A/S

Total return Current182%

Price return Current182%

MOMENTUM RATING↗

STRONG77 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+13%10

3-month return+30%10

YTD return+23%8

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+16%7

3-year return+7%3

5-year return-13%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 16% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+13%), over three months (+30%) and so far this year (+23%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+7.5% over three years and -13% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Genmab A/S. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GMABGenmab A/S

Revenue FY25$3.0B

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+21%9

Revenue, next 1Y+17%8

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+749%10

EPS growth, FY27E+26%8

EPS growth, FY28E+70%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 21%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 70%/yr vs revenue 18%/yr), so margins should widen.

WATCH

Revenue grew 21%/yr over the last 3 years; forecasts see it cooling to 18%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

GMABGenmab A/S

Total return Current182%

Price return Current182%

MOMENTUM RATING↗

STRONG77 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+13%10

3-month return+30%10

YTD return+23%8

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+16%7

3-year return+7%3

5-year return-13%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 16% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+13%), over three months (+30%) and so far this year (+23%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+7.5% over three years and -13% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Genmab A/S. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Genmab A/S

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Genmab A/S. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Genmab A/S. Get the full investment case.

Premium